Sam Lai
Company: UNC Eshelman School of Pharmacy
Job title: Professor, Division of Pharmacoengineering & Molecular Pharmaceutics
Bio:
Sam is Professor directing a dynamic and highly multidisciplinary research group at UNC – Chapel Hill. His previous work has spawn multiple new areas of research, formed the basis of multiple publicly-traded companies, and his inventions have culminated in multiple FDA-approved drugs (including PEGylated drug products) as well as active clinical trials. He is an expert on anti-PEG antibodies, and was among the first to rigorously assess the prevalence of pre-existing anti-PEG antibodies among the general population, and to elucidate the biophysical mechanisms underpinning the PEG-specificity. He has developed standardized assays for assessing different anti-PEG antibody isotypes, and is part of NIH-led clinical studies to assess PEG immunogenicity by COVID mRNA vaccines.
Seminars:
Assays for Elucidating Anti-PEG Antibodies & Formulations to Overcome Anti-PEG Immunity 1:30 pm
Substantial variations in assay methods and sensitivities can limit conclusions drawn about anti-PEG immunity There are pre-existing anti-PEG antibodies, which makes well-characterized and standardizable assays an important part of rigorous evaluation of PEG immunogenicity PEG-immunogenicity can be altered by formulation NEW DATA, NEW COMPANYRead more
day: Conference Day Two
